hVIVO plc (LSE:HVO) has spent 2026 rebuilding its contracted workload after a bruising 2025, and the numbers now tell two different stories. First-half Revenue fell by a third and adjusted EBITDA turned negative, yet the orderbook more than doubled from £30m to £65m in six months, and on 27 August 2026 the group added a third German clinical research unit by acquiring CRS Berlin.
For a company until recently almost synonymous with human challenge trials, the shift to a broader clinical development platform is the key question. With the shares at roughly 8.4p and a Market Capitalisation near £58m, according to lse.co.uk on 2 September 2026, the market values hVIVO at little more than a year's revenue. Whether the promised second-half recovery arrives is what matters next.
CRS Berlin deal extends the German footprint into dermatology and women's health
On 27 August 2026 hVIVO announced the Acquisition of CRS Clinical Research Services Berlin GmbH, an early-phase unit specialising in dermatology and women's health. The structure is capital-light: an upfront payment of just €0.025m, then an earn-out of 18% of CRS Berlin's annual revenue for 2026 to 2028. hVIVO expects the earn-out to total around €6m gross, less a €2m pension Liability assumed with the business, leaving expected net payments of roughly €4m.
CRS Berlin generated revenue of €10m in 2025 with unaudited EBITDA of €0.3m and net Assets of €0.1m, and had a contracted orderbook of €10m at 30 June 2026. hVIVO says the deal is immediately Earnings accretive, will add to FY2026 revenue and EBITDA, and should be self-funding from contracted work.
Strategically, the deal sits alongside the CRS units in Mannheim and Kiel bought in January 2025 and opens up a Berlin catchment of around 6.2 million people for patient recruitment. Chief executive Yamin "Mo" Khan said: "Dermatology and women's health are large and strategically attractive areas of drug development, and CRS Berlin brings specialist capabilities in both." The company also flagged cross-selling opportunities across its CRS network and UK laboratories.
From challenge-trial specialist to full-service clinical development partner
hVIVO describes itself as a full-service international clinical development partner and the global leader in human challenge trials, in which healthy volunteers are deliberately infected with a well-characterised virus under Quarantine to test vaccines and antivirals quickly. The group says it works with seven of the world's ten largest biopharma companies.
It now runs four integrated service lines: consulting; clinical trials, spanning Phase I/II CRO work and Phase II/III site services; human challenge trials; and laboratories offering virology, immunology and biobanking, including a bacterial laboratory at Canary Wharf completed in 2025. The £3.2m Cryostore acquisition added temperature-controlled sample storage.
Revenue is recognised as contracted studies progress at facilities in the UK and Germany, and the group is debt-free. Geography matters: North American revenue fell to £18.0m in FY2025 from £43.1m a year earlier, showing how sensitive hVIVO is to US biotech funding and big-pharma pipeline decisions.
FY2025 results and H1 2026 trading: a transitional year, then a heavier second-half bet
Final results for the year to 31 December 2025, published on 15 April 2026, showed revenue of £46.8m, down 25% from £62.7m in FY2024. Adjusted EBITDA collapsed to £1.4m from £16.4m, and the group swung to an operating loss of £4.6m from a £12.9m profit. Loss before tax was £4.5m (FY2024: profit of £13.3m), giving Basic Earnings Per Share of minus 0.87p versus 1.57p. CRS, consolidated from 28 January 2025, contributed £13.1m of revenue, and exceptional acquisition and reorganisation costs totalled £1.4m.
Cash fell to £14.3m at year-end from £44.2m, after the €10.0m (about £8.4m) CRS Mannheim and Kiel purchase and the Cryostore deal, with no debt. The board paid no Dividend for 2025, prioritising reinvestment. The year-end orderbook was £30m, down from a restated £43.5m. Mr Khan called 2025 "a year of significant strategic progress" whose performance "reflected the anticipated transitional nature of the period, against a backdrop of macroeconomic and sector headwinds".
The H1 2026 trading update on 23 July 2026 confirmed the trough. Revenue for the six months to 30 June 2026 was £16.3m, against £24.2m in H1 2025, and adjusted EBITDA was a negative mid-single-digit-million figure compared with a positive £3.0m. Cash was around £13m. The offsetting news was commercial: the orderbook reached £65m, proposal volumes rose roughly 45% year on year, and management reiterated guidance for high single-digit revenue growth in FY2026 with positive adjusted EBITDA in the second half, while noting modest deferrals of some contracted programmes into 2027.
What could drive the stock next?
The arithmetic of the guidance is demanding. High single-digit growth on £46.8m implies FY2026 revenue of roughly £50m to £51m, which after a £16.3m first half requires second-half revenue of around £34m to £35m, about double H1. Delivering that ramp is the single most important catalyst, and the interim results following the July update will show how far contracted work has begun converting.
The pipeline underpinning it is visible. On 22 April 2026 hVIVO signed a pivotal Phase III human challenge trial with ILiAD Biotechnologies for its BPZE1 whooping cough vaccine, involving more than 500 volunteers with most revenue expected across 2026 and 2027. A £6m influenza challenge study for an undisclosed monoclonal antibody developer followed on 7 May 2026, after a Traws Pharma influenza contract signed early in the year. Further wins of that scale, early CRS Berlin cross-selling, growth in the cardiometabolic specialism (about 30% of CRS contract wins in 2025) and scaling of standalone laboratory services are the levers management has identified.
Risks investors should watch
The most obvious risk is timing. hVIVO has already acknowledged deferrals from H2 2026 into 2027, and challenge studies depend on volunteer recruitment, regulatory clearances and sponsor readiness, none of which the company fully controls. A further slip would leave FY2026 short of guidance and the group loss-making for a second year.
Cash has fallen from £44.2m to about £13m in eighteen months. With no Debt there is no immediate financing pressure, but a negative-EBITDA first half shows the burn can be meaningful when utilisation is low. Customer concentration is another factor: the collapse in North American revenue shows how a few sponsor decisions can move the Top Line by tens of millions.
The German expansion adds integration and Margin risk: CRS Berlin earned only €0.3m of EBITDA on €10m of revenue in 2025, and the assumed €2m pension liability is a real cost. A sub-£60m AIM Market Value also means limited Liquidity and a wide bid-offer spread.
Outlook
hVIVO (LSE:HVO) enters the final months of 2026 with a record orderbook, a broader service mix and a management team that has staked its credibility on a second-half recovery. The interim results and any updated guidance will show whether £65m of contracted work is converting into revenue and positive adjusted EBITDA on schedule. Investors should also watch the pace of new challenge-trial signings, the early contribution from CRS Berlin and the cash trajectory. The strategic logic of the platform is clearer than a year ago; the financial proof is still to come.



_11_18_2026_14_37_47_487896.jpg)


Please wait processing your request...